



**Dr. David Haylock**  
**Associate Professor, Australian Stem Cell Centre (Australia)**

**Biography**

Associate Professor David N Haylock has extensive knowledge and expertise in the biology of human haemopoietic stem and progenitor cells. He made the initial observation that haemopoietic recovery following high dose induction chemotherapy for acute myeloid leukaemia was associated with a dramatic increase in the level of circulating haemopoietic progenitor cells. In collaboration with Drs Juttner and To, he pioneered autologous transplantation with mobilised blood progenitor cells, a technique that has since revolutionised haemopoietic transplantation. During the last decade, Associate Professor Haylock has focused on ex vivo manipulation of haemopoietic stem and progenitor cells for therapeutic purposes. His studies include describing the requirement of simultaneous stimulation by combinations of soluble recombinant haemopoietic growth factors for division of primitive human haemopoietic progenitors.

From 2000-2005, as Head of Experimental Cell Therapy at the Peter MacCallum Cancer Centre, Associate Professor Haylock lead Australia's first clinical trial with ex vivo expanded CD34+ cells in the setting of repetitive high dose chemotherapy for metastatic breast cancer. He was appointed as the Director of the Major National Research Facility Division of the Australian Stem Cell Centre in 2004 and continues to participate in fundamental research on haemopoietic stem cells and the haemopoietic stem cell niche in collaboration with Associate Professor Susie Nilsson. Associate Professor Haylock is currently a member of the scientific steering committee overseeing the Bioconsortium component of the CRC for Polymers which is synthesizing and testing innovative polymer based materials and surfaces for propagation of embryonic and adult stem cells.